Chronic Pancreatitis – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2021 To 2032

Chronic Pancreatitis Market Outlook

Thelansis’s “Chronic Pancreatitis Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2021 To 2032" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Chronic Pancreatitis treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).

Chronic Pancreatitis Overview

Chronic pancreatitis is a progressive inflammatory condition that results in the irreversible destruction of both exocrine and endocrine pancreatic tissue, typically due to atrophy or its replacement with fibrous tissue. This disorder gives rise to significant functional consequences, including intense abdominal pain, diabetes mellitus, and malabsorption of nutrients. Chronic pancreatitis can be triggered by various factors, including alcohol abuse, blockage of the pancreatic ducts (caused by malignancies, stones, or trauma), genetic predisposition, chemotherapy, and autoimmune diseases such as systemic lupus erythematosus (SLE) or autoimmune pancreatitis. Laboratory tests used for diagnosing chronic pancreatitis encompass a complete blood count (CBC), basic metabolic panel (BMP), liver function tests (LFTs), lipase, amylase, lipid panel, and measurement of fecal elastase-1 levels. Lipase and amylase levels may exhibit elevation, although they tend to be normal due to significant pancreatic scarring and fibrosis. The primary goal of treatment includes reducing abdominal pain and addressing malabsorption. The pain experienced by individuals with chronic pancreatitis arises from inflammation, neuropathic mechanisms, and obstructed ducts. Dietary recommendations typically involve consuming small, frequent, low-fat meals and supplementing fat-soluble vitamins and pancreatic enzymes. Surgical intervention to resect the pancreas can yield positive outcomes when performed by experienced surgeons. However, it's worth noting that the procedure carries a mortality rate exceeding 10%, and the quality of life is compromised without a properly functioning pancreas. In cases where there is persistent and worsening abdominal pain, a comprehensive differential diagnosis is considered. This includes conditions such as peptic ulcer disease, cholelithiasis, biliary obstruction or colic, acute pancreatitis, pancreatic malignancy, pseudocyst formation, and chronic mesenteric ischemia. The prognosis for chronic pancreatitis is significantly affected by ongoing alcohol use, smoking, and end-stage liver disease. Ten years after diagnosis, there is a survival rate of 70%, which decreases to 45% at the 20-year mark. Notable complications include pseudocyst formation and mechanical obstructions of the bile duct and duodenum.

• In the United States, the annual incidence of chronic pancreatitis is approximately 24.7 cases per 100,000 individuals in the adult population and 1.9 cases per 100,000 in the pediatric population.

Geography Covered:

North America- the United States and Canada

Europe- EU5 (Germany, France, Italy, Spain, and the United Kingdom)

Other countries- Japan & China

Study Period: 2021-2032

Current Clinical Practice and Treatment Algorithm

This section of the study covers country-specific current clinical practice, the standard of care, and significant limitations around addressing the unmet needs. Retrospective analysis and bench-marking of clinical study outcomes are presented in terms of Pre-treatment & post-treatment clinical and demographic patient characteristics. Essentially, this section will cover the evolution of the current competitive landscape and its impact on the future treatment paradigm.

KOL Insights:

KOLs across 8 MM markets from the center of Excellence/ Public/ Private hospitals participated in the study. Insights around current treatment landscape, epidemiology, clinical characteristics, future treatment paradigm, and Unmet needs

Market Forecast: Patient Based Forecast Model (MS. Excel Based Automated Dashboard)

- Data Inputs with sourcing

- Market Event and Product Event

- Country-specific Forecast Model

- Market uptake and patient share uptake

- Attribute Analysis

- Analog Analysis

- Disease burden and pricing scenario

- Summary and Insights

NPV/ IRR Calculator-

Optimization of cash flow/ revenue flow concerning all fixed and variable investments throughout the product development process. The rate of return on an investment is a critical indicator to ensure the profitability and break-even of the project.

Competitive Landscape:

The competitive landscape includes country-specific approved as well as pipeline therapies. Any asset/product-specific designation or review such as Orphan drug designation, Fast track, Priority Review, Breakthrough Therapy Designation, Rare Pediatric Disease Designation, and Accelerated Approval are tracked and supplemented with analyst commentary.

Clinical Trial Assessment-

Detailed clinical trial data analysis and critical product positioning include trial design, primary outcomes, secondary outcomes, dosing and schedules, inclusion and exclusion criteria, recruitment status and essentially covers the reported adverse events. Majorly the trial analysis helps determine the potential of the critical assets and their probable filing and launch date.

Unmet Medical Needs Overview-

This report presents the most important clinical unmet needs in the treatment, according to Thelansis research and analysis. Other essential unmet needs identified through our study include decreased cost burden on patients, improved administration convenience, and improved patient compliance.

Visit our social media pages: